Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

NCT05077215 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Endometrial Cancer

Interventions

DRUG: EG-007
DRUG: Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection
DRUG: Lenvatinib Capsules

Sponsor

Evergreen Therapeutics, Inc.